In order to find out for whom the GAD alum could work well, the DIAGNODE 1 and -2 studies were set up in 2018. The first results of the DIAGNODE-1 study in 12 patients show a positive course of the disease and also that GAD alum is well tolerated by patients after being injected directly into the lymph node in combination with treatment with vitamin D. The DIAGNODE-2 study, a randomized controlled trial, has started early 2019 and 80 patients are participating in this study. Diabeter is also participating in this study.
Topline results from DIAGNODE2 study are expected in September 2020. Click here for the press release.